Investor's Business Daily on MSN

BioMarin soars 18% after folding in the $4.8 billion takeover of Amicus

BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novan (NOVN), Avidity Biosciences (RNA) and Insmed (INSM)

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.